Search Result

Results for "

antitumor+effect

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) Akt (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (1) Apoptosis (15) Aurora Kinase (1) Autophagy (1) Bacterial (1) Bcl-2 Family (1) Casein Kinase (1) CDK (5) Deubiquitinase (1) DNA Alkylator/Crosslinker (2) DNA/RNA Synthesis (2) Drug Derivative (2) Dynamin (1) Endogenous Metabolite (2) Epigenetic Reader Domain (1) ERK (2) Estrogen Receptor/ERR (1) Ferroptosis (1) FLT3 (1) Fungal (1) Glutathione Peroxidase (1) Glycosidase (1) Hedgehog (1) Hexokinase (1) Histamine Receptor (4) Histone Methyltransferase (2) IGF-1R (1) Isotope-Labeled Compounds (1) JAK (1) JNK (1) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (2) P-glycoprotein (1) PARP (2) Photosensitizer (1) PI3K (2) PROTACs (2) Quinone Reductase (1) RAR/RXR (1) Ras (3) Reactive Oxygen Species (ROS) (2) Reference Standards (5) Ser/Thr Protease (1) STAT (1) Toll-like Receptor (TLR) (2) Wnt (1)
By Research Areas:	Cancer (48) Endocrinology (2) Inflammation/Immunology (7)

By Targets:

ACSL Family (1)

Akt (1)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (1)

Apoptosis (15)

Aurora Kinase (1)

Autophagy (1)

Bacterial (1)

Bcl-2 Family (1)

Casein Kinase (1)

CDK (5)

Deubiquitinase (1)

DNA Alkylator/Crosslinker (2)

DNA/RNA Synthesis (2)

Drug Derivative (2)

Dynamin (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (1)

ERK (2)

Estrogen Receptor/ERR (1)

Ferroptosis (1)

FLT3 (1)

Fungal (1)

Glutathione Peroxidase (1)

Glycosidase (1)

Hedgehog (1)

Hexokinase (1)

Histamine Receptor (4)

Histone Methyltransferase (2)

IGF-1R (1)

Isotope-Labeled Compounds (1)

JAK (1)

JNK (1)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (2)

P-glycoprotein (1)

PARP (2)

Photosensitizer (1)

PI3K (2)

PROTACs (2)

Quinone Reductase (1)

RAR/RXR (1)

Ras (3)

Reactive Oxygen Species (ROS) (2)

Reference Standards (5)

Ser/Thr Protease (1)

STAT (1)

Toll-like Receptor (TLR) (2)

Wnt (1)

By Research Areas:

Cancer (48)

Endocrinology (2)

Inflammation/Immunology (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10008

SNS-032 Maximum Cited Publications 11 Publications Verification BMS-387032	CDK Apoptosis	Cancer
SNS-032 (BMS-387032) is a potent and selective inhibitor of CDK2, CDK7, and CDK9 with IC₅₀s of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect .

HY-134929

Benitrobenrazide 2 Publications Verification BNBZ; Hexokinase 2 inhibitor 1	Hexokinase Apoptosis	Cancer
Benitrobenrazide (BNBZ) is the orally active inhibitor for hexokinase 2 with an IC₅₀ of 0.53 µM. Benitrobenrazide causes DNA damage, and exhibits antitumor effect .

HY-129071

Vindesine sulfate	Microtubule/Tubulin	Cancer
Vindesine sulfate is a potent tubulin inhibitor with an K_i of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo .

HY-131493

PF-06939999 PRMT5-IN-3	Histone Methyltransferase Apoptosis	Cancer
PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC₅₀ in A427 is 1.1 nM). PF-06939999 exhibits antitumor effect .

HY-18285

Longdaysin	Wnt Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .

HY-N2112

Glaucocalyxin A 2 Publications Verification	PI3K Akt Apoptosis	Cancer
Glaucocalyxin A, an ent-kauranoid diterpene from Rabdosia japonica var., induces apoptosis in osteosarcoma by inhibiting nuclear translocation of Five-zinc finger Glis 1 (GLI1) via regulating PI3K/Akt signaling pathway. Glaucocalyxin A has antitumor effect .

HY-17576

Satraplatin 1 Publications Verification BMS182751; BMY45594; JM216	DNA Alkylator/Crosslinker	Cancer
Satraplatin is an alkylating agent, with potent antitumor effect.

HY-N7698B

Hexa-N-acetylchitohexaose	Glycosidase	Inflammation/Immunology Cancer
Hexa-N-acetylchitohexaose is an inducer of disease resistance in crop plants, which could elicit an increase of lignification-related and antioxidative enzymes in soybean plants. Hexa-N-acetylchitohexaose is a substrate of lysozyme. Hexa-N-acetylchitohexaose shows antitumor effect .

HY-110120

DSR-6434 1 Publications Verification	Toll-like Receptor (TLR)	Cancer
DSR-6434 is a potent and selective Toll-like receptor 7 (TLR7) agonist, with EC₅₀s of 7.2 nM and 4.6 nM for human and mice TLR7, respectively. DSR-6434 has a strong antitumor effect .

HY-125390

SM-360320 CL-087	Toll-like Receptor (TLR)	Inflammation/Immunology Cancer
SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .

HY-110215

XD14	Epigenetic Reader Domain	Cancer
XD14 is a potent BET inhibitor with antitumor effect. It binds to BRD2, BRD3, and BRD4 with K_ds of 170, 380, and 160 nM, respectively .

HY-B0971

Pheniramine maleate Prophenpyridamine maleate; Tripoton maleate	Histamine Receptor Apoptosis	Inflammation/Immunology Endocrinology
Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

HY-163081

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of PARP7 with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-170863

ZSH-2208	RAR/RXR	Cancer
ZSH-2208 is an analog of retinoic acid A, which exerts a potent antitumor effect on regenerative stem cells (TRCs) of esophageal squamous cell carcinoma (ESCC) through RARγ-TNFAIP3 .

HY-145737A

PROTAC SOS1 degrader-1 TFA	PROTACs Ras	Cancer
PROTAC SOS1 degrader-1 (TFA) is a potent PROTAC SOS1 degrader with an DC₅₀ of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .

HY-168528

WS-917 1 Publications Verification	P-glycoprotein	Cancer
WS-917 is a potent and orally active ABCB1 modulator. WS-917 enhances ABCB1 ATPase activity. WS-917 significantly enhances the antitumor effect of paclitaxel combined with anti-PD-1 antibody. WS-917 promotes CD8 ⁺ T-cell activation .

HY-171272

PRDX1-IN-3	Reactive Oxygen Species (ROS) MDM-2/p53	Cancer
PRDX1-IN-3 (compound 19-048) is a PRDX1 covalent inhibitor with anti-colorectal cancer activity. PRDX1-IN-3 can effectively inhibit the proliferation of colorectal cancer cells, and its antitumor effect on nude mice with colorectal cancer carrying PRDX1 gene knockout is significantly reduced. PRDX1-IN-3 also upregulates the downstream genes of the p53 signaling pathway to exert an anticancer effect .

HY-135887

ZX-29	Anaplastic lymphoma kinase (ALK) Apoptosis Autophagy	Cancer
ZX-29 is a potent and selective ALK inhibitor with an IC₅₀ of 2.1 nM, 1.3 nM and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. ZX-29 is inactive against EGFR. ZX-29 induces apoptosis by inducing endoplasmic reticulum (ER) stress and overcomes cell resistance caused by an ALK mutation. ZX-29 also induces protective autophagy and has antitumor effect .

HY-173059

CDK12/13-IN-3	CDK	Cancer
CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for CDK that inhibits CDK12 and CDK13 with IC₅₀ of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC₅₀ of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6% .

HY-145737

PROTAC SOS1 degrader-1	PROTACs Ras	Cancer
PROTAC SOS1 degrader-1 is a potent PROTAC SOS1 degrader with an DC₅₀ of 98.4 nM. PROTAC SOS1 degrader-1 shows antiproliferation activity in cancer cells with various KRAS mutations. PROTAC SOS1 degrader-1 shows antitumor effect with low toxicity .

HY-B0971A

Pheniramine Prophenpyridamine; Tripoton; Pheniramine solution	Histamine Receptor Apoptosis	Inflammation/Immunology Cancer
Pheniramine (Prophenpyridamine;Tripoton) is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine displays antitumor effect and induces leukemia cells apoptosis. Pheniramine is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

HY-177306

Opitor-0	Dynamin	Cancer
Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase) with an IC₅₀ of 3 μM. Opitor-0 can induce fragmentation of mitochondria and remodeling of cristae, disrupt the stability of OPA1 oligomers, and significantly enhance the release of cytochrome c and induce apoptosis. Opitor-0 has a synergistic antitumor effect with Bcl-2 inhibitors, such as ABT-737 (HY-50907) and Venetoclax (HY-15531). Opitor-0 can be used for the research of malignant tumors that are resistant to Bcl-2 inhibitors, such as triple-negative breast cancer (TNBC) .

HY-N14389

Fluoroindolocarbazole C	Others	Cancer
Fluoroindolocarbazole C is found in the strain of Saccharothrothrix aerocolonigenes ATCC 39243. Fluoroindolocarbazole C has antitumor effect .

HY-119527

Conagenin	Endogenous Metabolite	Inflammation/Immunology Cancer
Conagenin is an immunomodulator. Conagenin shows antitumor effects by activation of T cells and increasing antitumor effector cells .

HY-131126S

Metolcarb-d3	Isotope-Labeled Compounds	Others
Metolcarb-d₃ is the deuterium labeled Herniarin. Herniarin is a natural coumarin occurs in some flowering plants, with antitumor effect.

HY-14115

Hedgehog IN-10	Hedgehog	Cancer
Hedgehog IN-10 (compound 24) is a potent Hedgehog inhibitor. Hedgehog IN-10 exhibits significant antitumor effect .

HY-W669548

Antitumor agent-193	Drug Derivative	Cancer
Antitumor agent-193 (Compound 13) has antitumor effect, but has no activity against normal cell line MRC-5 .

HY-129234

Mazethramycin	Antibiotic Bacterial Fungal DNA/RNA Synthesis	Cancer
Mazethramycin is an antitumor antibiotic that exerts its antitumor effect by interfering with cellular DNA replication and RNA synthesis. Mazethramycin can be used in cancer research .

HY-123371

Ro 07-1902	DNA Alkylator/Crosslinker	Cancer
Ro 07-1902 is an effective antitumor potentiator that can significantly enhance the antitumor effect of CCNU (HY-13669) against KHT sarcoma at low doses .

HY-105969

Dichloromethotrexate NSC-29630; 3',5'-Dichloromethotrexate	Drug Derivative	Cancer
Dichloromethotrexate (NSC-29630), an orally active antitumor agent, shows antitumor effect against L1210 leukemia and C3H lymphosarcoma in mice .

HY-126048

JTP-70902	MEK	Cancer
JTP-70902, a p15 ^INK4b-inductive compound, is a MEK1/2 inhibitor. JTP-70902 exhibits potent antitumor effect .

HY-146267

ERα degrader 5	Estrogen Receptor/ERR	Cancer
ERα degrader 5 (Compound 40) is a selective, orally bioavailable estrogen receptor (ER) degrader (SERD) with an EC₅₀ of 1.1 nM against ERα. ERα degrader 5 shows antitumor effect in vivo .

HY-162003

DCPT1061	Histone Methyltransferase	Cancer
DCPT1061 potently inhibits PRMT1, PRMT6 and PRMT8 in vitro with less inhibitory effect on PRMT3, PRMT4, and PRMT5 or other epigenetic enzymes. DCPT1061 has antitumor effect .

HY-146406

Anticancer agent 52	Apoptosis	Cancer
Anticancer agent 52 is a potent anticancer agent. Anticancer agent 52 shows in vitro cytotoxicity. Anticancer agent 52 induces apoptosis. Anticancer agent 52 shows antitumor effect. Anticancer agent 52 has the potential for the research of bladder cancer .

HY-129071R

Vindesine sulfate (Standard)	Reference Standards Microtubule/Tubulin	Cancer
Vindesine (sulfate) (Standard) is the analytical standard of Vindesine (sulfate). This product is intended for research and analytical applications. Vindesine sulfate is a potent tubulin inhibitor with an Ki of 0.110 μM. Vindesine sulfate shows anti-proliferation effect in vitro. Vindesine sulfate shows antitumor effect in vivo .

HY-123542

ONO-3403	Ser/Thr Protease Apoptosis	Cancer
ONO-3403 is an orally active serine protease inhibitor. ONO-3403 inhibits the production of TNF-α and nitric oxide induced by LPS. ONO-3403 inhibits the cell growth and induces the apoptosis, and has an antitumor effect on malignant tumors .

HY-10008R

SNS-032 (Standard) BMS-387032 (Standard)	Reference Standards CDK Apoptosis	Cancer
SNS-032 (Standard) is the analytical standard of SNS-032. This product is intended for research and analytical applications. SNS-032 (BMS-387032) is a potent and selective inhibitor of?CDK2, CDK7, and CDK9 with?IC50s?of 38 nM, 62 nM and 4 nM, respectively. SNS-032 has antitumor effect .

HY-B0971R

Pheniramine maleate (Standard) Prophenpyridamine maleate (Standard); Tripoton maleate (Standard); Pheniramine maleate (Standard)	Reference Standards Histamine Receptor Apoptosis	Inflammation/Immunology Endocrinology
Pheniramine (maleate) (Standard) is the analytical standard of Pheniramine (maleate). This product is intended for research and analytical applications. Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

HY-N7814R

2-Hydroxypalmitic acid (Standard)	Reference Standards Endogenous Metabolite	Others
Pheniramine (maleate) (Standard) is the analytical standard of Pheniramine (maleate). This product is intended for research and analytical applications. Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

HY-B0971AR

Pheniramine (Standard) Prophenpyridamine (Standard); Tripoton (Standard); Pheniramine solution (Standard)	Reference Standards Histamine Receptor Apoptosis	Inflammation/Immunology Cancer
Pheniramine (Standard) is the analytical standard of Pheniramine. This product is intended for research and analytical applications. Pheniramine (Prophenpyridamine;Tripoton) is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine displays antitumor effect and induces leukemia cells apoptosis. Pheniramine is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

HY-155851

Lepadin E	Ferroptosis MDM-2/p53 Glutathione Peroxidase ACSL Family	Cancer
Lepadin E is a significantly cytotoxic ferroptosis inducer that induces iron death through the classical p53-SLC7A11-GPX4 pathway. Lepadin E promoted p53 expression, decreases SLC7A11 and GPX4 levels, and leads to increased ROS and lipid peroxide production, and upregulated ACSL4 expression, thus causes cell death. Lepadin E has significant antitumor effect .

HY-150596

CT1-3	Apoptosis Bcl-2 Family JNK	Cancer
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity .

HY-155730

PI3K-IN-41	PI3K	Cancer
PI3K-IN-41 (compound 2) is a photocaged compound, as well as a photocaged PI3K inhibitor (IC₅₀=18.92 nM) with anticancer properties. PI3K-IN-41 has potential to be used in precisely controlled cancer therapeutics. PI3K-IN-41 exhibits potent PI3K ihibition upon UV light irradiation, and enhances antitumor effect .

HY-115904

FLT3/CDK4-IN-1	CDK FLT3	Cancer
FLT3/CDK4-IN-1 is a potent, high selective and orally active FLT3/CDK4 dual inhibitor (IC₅₀=11 and 7 nM for FLT3 and CDK4, respectively). FLT3/CDK4-IN-1 has antiproliferative activities against certain cancer cells. FLT3/CDK4-IN-1 has good antitumor effect in vivo .

HY-173047

KRASG12C IN-15	Ras ERK	Cancer
KRASG12C IN-15 (Compound 21) is the orally active inhibitor for KRAS ^G12C, and inhibits SOS1-mediated GDP/GTP exchange with an IC₅₀ of 19 nM. KRASG12C IN-15 inhibits the phosphorylation of ERK with IC₅₀ of 0.051 μM. KRASG12C IN-15 inhibits the cell viability of KRAS ^G12C mutated MIA PaCa-2 with IC₅₀ of 0.023 μM. KRASG12C IN-15 exhibits antitumor effect in MIA PaCa-2 xenograft mouse models .

HY-170927

JAK-IN-40	JAK STAT Apoptosis	Cancer
JAK-IN-40 (Compound 46) is the inhibitor for JAK that inhibits JAK1, JAK2 and JAK3 with IC₅₀s of 0.022, 0.759 and 1.601 μM, respectively. JAK-IN-40 inhibits the phosphorylation of STAT3. JAK-IN-40 inhibits the proliferation of cancer cell Ba/F3 and JAK1-TEL Ba/F3 with GI₅₀ of 0.614 μM and 0.193 μM. JAK-IN-40 arrests cell cycle of H1975 and H2087 at G2/M phase, induces apoptosis. JAK-IN-40 exhibits a synergistic antitumor effect with Osimertinib (HY-15772) .

HY-167854

KW-2450 free base	Aurora Kinase Apoptosis IGF-1R	Cancer
KW-2450 Free base is a potent multikinase inhibitor targeting Aurora A and B kinases, demonstrating significant antitumor activity against triple-negative breast cancer (TNBC). KW-2450 Free base effectively reduces cell viability, promotes apoptosis, and inhibits colony formation and mammosphere formation in TNBC cells. KW-2450 Free base significantly suppresses the growth of TNBC xenografts, leading to tetraploid accumulation followed by apoptosis or the survival of octaploid cells. KW-2450 Free base enhances the efficacy of combination therapy with the MEK inhibitor selumetinib, resulting in a synergistic antitumor effect in TNBC models. KW-2450 Free base also acts as an orally bioavailable inhibitor of IGF-1R and IR tyrosine kinases, contributing to its potential antineoplastic activity by inhibiting tumor cell proliferation and inducing apoptosis.

HY-N14385

Fluoroindolocarbazole A	Others	Cancer
Fluoroindolocarbazole A is found in the strain of Saccharothrothrix aerocolonigenes ATCC 39243. Fluoroindolocarbazole A has antitumor effect .

HY-N14388

Fluoroindolocarbazole B	Others	Cancer
Fluoroindolocarbazole B is found in the strain of Saccharothrothrix aerocolonigenes ATCC 39243. Fluoroindolocarbazole B has antitumor effect .

HY-183078

P6620	Deubiquitinase	Cancer
P6620 is an orally active USP7 inhibitor. P6620 specifically binds to USP7 and disrupts its interaction with LRRC41. P6620 exhibits anticancer activity against hepatocellular carcinoma. P6620 enhances the antitumor effect of Lenvatinib (HY-10981) in xenograft mouse models. P6620 can be used for the research of hepatocellular carcinoma .

Cat. No.	Product Name	Category	Target	Chemical Structure